Toll Free: 1-888-928-9744
Published: Apr, 2017 | Pages:
126 | Publisher: GMR Data
Industry: Pharmaceutical | Report Format: Electronic (PDF)
GMR Data’s new Pharmaceutical report is released today detailing The Brazil, Russia, India and China Over-the-Counter Pharmaceuticals Market to 2025. The report draws on knowledge of experts in the field, in depth company research and up to date tracking of trends in the OTC sector. By exploring and comparing these key 4 markets GMR Data aim to give the reader the best indication of how these markets will progress to 2025; which OTC areas will offer the most growth and what location specific issues any entrant to the respective OTC markets can face. In this brand new 126-page report you will receive 70 tables and 35 figures - all unavailable elsewhere. By ordering and reading our brand new report today you stay better informed and ready to act. The report provides clear detailed insight into the BRIC OTC. Discover the key drivers and challenges affecting the market. Drivers include • Growing awareness of OTC products amongst consumers • Increasing purchasing power parity of the consumers • Increasing NCD population will drive OTC demand in BRIC nations Restraints include • Stringent regulations • Infrastructural Challenges - distribution networks The income disparity in emerging BRIC countries is comparatively high when compared to developed nations. This is the fundamental challenge faced by multinationals operating in these markets. Whereas growing populations and increasing consumer awareness for self-medication are important factors driving the demand. GMR Data’s The Brazil, Russia, India and China Over-the-Counter Pharmaceuticals Market to 2025 also benefits from 3 exclusive interviews with representatives from; • Novartis • Ranbaxy • Sanofi These leading, in the field, experts offer exclusive insight into the BRIC OTC sector; how they see the market currently, which geographical areas will witness growth and which sub sectors / OTC drugs face perhaps face an uncertain growth trajectory. With the growing economies of the BRIC countries, the purchasing power of the general population is increasing, which in turn increases the market size for OTC products.
Table of Contents The Brazil, Russia, India & China Over-the-Counter Pharmaceutical Market to 2025 1 - Executive Summary 1.1 Executive Summary 1.2 Research and Analysis Methods 1.3 Drivers & Restraints of the BRIC OTC Market to 2025 1.3.1 Drivers 188.8.131.52 Growing awareness of OTC products amongst consumers 184.108.40.206 Increasing purchasing power parity of the consumers 220.127.116.11 Increasing elderly, smoking and obese population to drive OTC demand in BRIC 18.104.22.168 Favourable government regulations and promotion of OTC products in emerging markets 1.3.2 Restraints 22.214.171.124 Stringent regulatory actions 126.96.36.199 Infrastructural Challenges 2 - Introduction to the BRIC OTC Market to 2025 2.1 OTC Pharmaceuticals 2.1.1 Classification of OTC Pharmaceuticals in BRIC Nations 2.2 Market Segmentation of OTC Pharmaceuticals 3 - The BRIC OTC Market to 2025 3.1 Global OTC Pharmaceutical Market to 2025 3.2 Breakdown by OTC Segment, Globally, 2014 - 2025 3.3 BRIC OTC Pharmaceuticals Market Overview 3.3.1 Economic Indicators, BRIC Countries, 2013 3.4 BRIC OTC Pharmaceuticals Market, 2013-2025 3.4 The Brazil OTC Pharmaceuticals Market Overview to 2025 3.4.1 Overview of Brazil 3.4.2 Brazil OTC Pharmaceuticals Market, 2014-2025 3.4.3 Breakdown by Segment, Brazil, 2014 and 2025 188.8.131.52 Skin Care 184.108.40.206 CC&A 220.127.116.11 Analgesics 18.104.22.168 Vitamins, Minerals & Supplements (VM&S) 3.5 Drivers for OTC Pharmaceuticals Growth, Brazil 3.5.1 Expansion of distribution channels 3.5.2 Favourable government regulations for OTC 3.5.3 Affordability of OTC products 3.5.4 Increasing middle class 3.5.5 Increase in non-communicable disease 3.5.6 OTC Companies in Brazil 22.214.171.124 Aché Laboratórios Farmacêuticos 126.96.36.199 Hypermarcas 188.8.131.52 EMS 184.108.40.206 Apsen Farmacêutica 3.6 The Russia OTC Pharmaceuticals Market Overview, to 2025 3.6.1 Overview of Russia 3.6.2 Russia OTC Pharmaceuticals Market, 2013-2025 3.6.3 Breakdown By Segment, Russia 220.127.116.11 CC&A 18.104.22.168 Digestives 22.214.171.124 Analgesics 3.6.4 Key Domestic Companies in the Russian OTC Market 126.96.36.199 Pharmstandard JSC 3.6.5 Regulatory Environment, Russia 3.6.6 Drivers for OTC Pharmaceuticals Growth, Russia 188.8.131.52 Growing popularity of direct and online sales channels 184.108.40.206 Growing disposable income 220.127.116.11 Growing incidence of non-communicable diseases 3.7 The India OTC Market Overview, to 2025 3.7.1 Overview of India 3.7.2 India OTC Pharmaceuticals Market to 2025 3.7.3 Breakdown by Segment, India, 2013 and 2025 18.104.22.168 VM&S 22.214.171.124 Cough and Cold 126.96.36.199 Analgesics 3.7.4 Regulatory Environment, India 3.7.5 Drivers for OTC Pharmaceuticals Growth, India 188.8.131.52 Consumer behaviour 184.108.40.206 Wide distribution 220.127.116.11 Liberal regulatory procedures 18.104.22.168 Availability of OTC Products 22.214.171.124 Margins on OTC Products 3.8 The China OTC Market Overview to 2025 3.8.1 Overview of China 3.8.2 China OTC Pharmaceuticals Market to 2025 126.96.36.199 Cough, Cold & Allergy 188.8.131.52 VM&S 184.108.40.206 Analgesics 3.8.3 Breakdown by Segment, China, 2013 and 2025 3.8.4 Regulatory Environment, China 3.8.5 Drivers for OTC Pharmaceuticals Growth, China 220.127.116.11 Economic performance 18.104.22.168 Increase in smoking / obese population 22.214.171.124 Increase in the elderly population 126.96.36.199 Growth in consumer awareness and self-medication 4 - Leading companies in the BRIC OTC Market 4.1 Leading companies in the BRIC OTC Market 4.2 Bayer 4.2.1 Bayer’s Company Overview 4.2.2 Bayer’s Key OTC Products 4.2.3 Bayer’s Financial Performance 4.2.4 BRIC Developments from Bayer 4.3 Boehringer Ingelheim 4.3.1 Boehringer Ingelheim’s Company Overview 4.3.2 Boehringer Ingelheim’s Key OTC Products 4.3.3 Boehringer Ingelheim’s Financial Performance 4.3.4 BRIC Developments from Boehringer Ingelheim 4.4 GlaxoSmithKline (GSK) 4.4.1 GSK’s Company Overview 4.4.2 GSK Key OTC Products 4.4.3 GSK’s Financial Performance 4.4.4 BRIC Developments from GSK 4.5 Johnson & Johnson 4.5.1 Johnson & Johnson Company Overview 4.5.2 Johnson & Johnson Key OTC Products 4.5.3 Johnson & Johnson Financial Performance 4.5.4 BRIC Developments from Johnson & Johnson 4.6 Merck 4.6.1 Merck’s Company Overview 4.6.2 Merck’s Financial Performance 4.6.3 BRIC Developments from Merck 4.7 Novartis 4.7.1 Novartis’s Company Overview 4.7.2 Novartis Key OTC Products 4.7.3 Novartis’s Financial Performance 4.7.4 Recent BRIC Developments from Novartis 4.8 Perrigo 4.8.1 Perrigo’s Company Overview 4.8.2 Perrigo Key OTC Products 4.8.3 Perrigo’s Financial Performance 4.8.4 Recent BRIC Developments from Perrigo 4.9 Pfizer 4.9.1 Pfizer’s Company Overview 4.9.2 Pfizer Key OTC Products 4.9.3 Pfizer’s Financial Performance 4.9.4 Recent BRIC Developments from Pfizer 4.10 Procter & Gamble 4.10.1 Proctor & Gamble Company Overview 4.10.2 Proctor & Gamble Key OTC Products 4.10.3 Proctor & Gamble Financial Performance 4.10.4 Recent BRIC Developments from Procter & Gamble 4.11 Reckitt-Benckiser 4.11.1 Reckitt-Benckiser Company Overview 4.11.2 Reckitt-Benckiser Key OTC Products 4.11.3 Reckitt Benckiser’s Financial Performance 4.11.4 Recent Developments from Reckitt Benckiser 4.12 Sanofi 4.12.1 Sanofi’s Company Overview and Key products 4.12.2 Sanofi’s Key OTC Products 4.12.3 Sanofi’s Financial Performance 4.12.4 Recent Developments from Sanofi 5- SWOT Analysis of the BRIC OTC Market to 2025 5.1 SWOT Analysis 5.1.1 Strengths: 188.8.131.52 Regulators are encouraging OTC approvals 184.108.40.206 Strong potential of OTC portfolio 220.127.116.11 Economic Advantages 18.104.22.168 Growing consumer awareness and self-medication 22.214.171.124 Increased purchasing power in emerging markets 5.1.2 Weaknesses 126.96.36.199 High focus on prescription and generic drugs 188.8.131.52 OTC products are vulnerable to price fluctuations 184.108.40.206 Inadequate Investment in infrastructure 220.127.116.11 Lack of proper health insurance system in BRIC 18.104.22.168 Income disparity 22.214.171.124 Distribution network 5.1.3 Opportunities 126.96.36.199 Increase in the Number of Self-administering Patients 188.8.131.52 Opportunities in social media and online marketing 184.108.40.206 Strong growth in the emerging / BRIC markets 220.127.116.11 Demographic changes 18.104.22.168 Growing health problems such as smoking and obese population 22.214.171.124 Improving the healthcare system 5.1.4 Threats: 126.96.36.199 Resistance to OTC switching for some groups (CNS, CVS) 188.8.131.52 Competition from private label brands will reduce profits 184.108.40.206 Regulatory concerns 6- Expert Opinion 6.1 Novartis 6.2 Ranbaxy 6.3 Sanofi
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.